CHRS on Nasdaq

Coherus BioSciences (United States)

American biological products company based in Redwood City, founded in 2010. Summary from the record

Price unavailable

Last updated Oct 19, 2026.

Overview

2010Founded1

Compare with Editas Medicine, Voyager Therapeutics (United States) or FENNEC PHARMACEUTICALS INC., or pick any stock.

  • TickerCHRS on Nasdaq1
  • IndustryBiological Products, (No Diagnostic Substances)1
  • HeadquartersRedwood City1
  • Websitewww.coherus.com
  • Incorporated inDE3
  • Business addressC/O Dennis M. Lanfear, 333 Twin Dolphin Dr, Suite 600, Redwood City, Ca 940653
  • Filer categoryAccelerated filer, Smaller reporting company3

See how the biggest companies compare on our leaderboards

We are a fully integrated commercial-stage innovative oncology company with an approved next-generation programmed death receptor-1 (“PD-1”) inhibitor, LOQTORZI® (toripalimab-tpzi), and a pipeline that includes two mid-stage clinical candidates targeting liver, head and neck, colorectal and other cancers. Our strategy is to grow sales of LOQTORZI in nasopharyngeal carcinoma (“NPC”) and advance the development of new indications for LOQTORZI in combination with both our pipeline candidates as well as our partners, driving sales multiples and synergies from proprietary combinations. On May 29, 2025, we changed our corporate name from “Coherus BioSciences, Inc.” to “Coherus Oncology, Inc.” to better align with our exclusive focus on proprietary innovative immuno-oncology medicines following the completion of the recent divestitures of our biosimilar businesses.4 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

-429.5%Operating margin5
398.4%Net margin5
59.8%Revenue growth, 20255
275.4%Return on equity5

What sells

Revenue by product, business segment and region, as the company reports it to the SEC.

Products and services

Toripalimab brought in 97% of the revenue Coherus BioSciences (United States) broke down this way in fiscal 2025.

  1. Toripalimab$40.8M597%up 113% from 2024
  2. Product and Service, Other$1.3M53%down 82% from 2024
Products and services by year
Products and services20242025
Toripalimab$19.1M$40.8M
Product and Service, Other$7.3M$1.3M

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Cost of revenue3¢$13.8M
  • Research and development27¢$108.9M
  • Selling, general and admin25¢$100.6M
  • Interest2¢$9.0M
  • Profit42¢$168.0M

Out of $42.2M in revenue.5

Financial statements

Revenue67895$42.2M in 2025−88% since 2019
0$200.0M$400.0M$600.0M2019: $356.1M$356.1M20192020: $475.8M$475.8M2020+34%2021: $326.6M$326.6M2021−31%2022: $211.0M$211.0M2022−35%2023: $257.2M$257.2M2023+22%2024: $26.4M$26.4M2024−90%2025: $42.2M$42.2M2025+60%
Operating income67895-$181.1M in 2025
-$400.0M-$200.0M0$200.0M2019: $107.8M$107.8M20192020: $156.3M$156.3M2020+45%2021: -$263.9M-$263.9M20212022: -$256.9M-$256.9M2022−3%2023: -$203.2M-$203.2M2023−21%2024: -$199.7M-$199.7M2024−2%2025: -$181.1M-$181.1M2025−9%
Net income67895$168.0M in 2025+87% since 2019
-$400.0M-$200.0M0$200.0M2019: $89.8M$89.8M20192020: $132.2M$132.2M2020+47%2021: -$287.1M-$287.1M20212022: -$291.8M-$291.8M2022+2%2023: -$237.9M-$237.9M2023−18%2024: $28.5M$28.5M20242025: $168.0M$168.0M2025+489%

Every line of the income statement as filed: the last 2 fiscal years, latest first.5

Period ending2025-12-312024-12-31
Net revenue$42.2M$26.4M
Cost of goods sold$13.8M$8.7M
Research and development$108.9M$91.8M
Selling, general and administrative$100.6M$125.5M
Total costs and expenses$223.3M$226.0M
Loss from operations-$181.1M-$199.7M
Interest expense-$9.0M-$10.7M
Loss on debt extinguishment$0-$12.6M
Other income (expense), net$7.0M$7.6M
Loss from continuing operations before income taxes-$183.1M-$215.4M
Income tax provision$0$0
Net loss from continuing operations-$183.1M-$215.4M
Net income from discontinued operations, net of tax (Note 6)$351.1M$243.9M
Net income$168.0M$28.5M
Net loss from continuing operations - basic-$2-$2
Net loss from continuing operations - diluted-$2-$2
Net income from discontinued operations - basic$3$2
Net income from discontinued operations - diluted$3$2
Net income per share - Basic (In dollar per share)$1.43$0.25
Net income per share - Diluted (In dollar per share)$1.43$0.25
Basic (In shares)117.1M shares114.6M shares
Diluted (In shares)117.1M shares114.6M shares

Compare Coherus BioSciences (United States) with another company

Leadership

Who has led Coherus BioSciences (United States), and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Dennis M. Lanfear2015–now

President

  1. Dennis M. Lanfear2015–now

Chief financial officer

  1. Jean-Frederic Viret2014–2021
  2. McDavid Stilwell2021–2024
  3. Bryan J. McMichael2024–now

Chief operating officer

  1. Vincent R. Anicetti2018–2021
201520202025
Board members and other officers (26)

Former names

  • Coherus BioSciences, Inc.Jan 14, 2013 to May 28, 20253
  • BioGenerics, Inc.Feb 23, 2011 to Jan 3, 20123

Timeline

  1. Mar 12, 2015New chief executive Dennis M. Lanfear becomes CEO13
  2. 2010Founded Founded1

Filings

334 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 87 major events, 115 insider forms, 37 large holders, 75 other. The latest 20:

  1. Aug 28, 20268-K EDGAR
  2. Aug 28, 2026424B5 EDGAR
  3. Aug 28, 2026424B3 EDGAR
  4. Aug 17, 20268-K EDGAR
  5. Aug 17, 20268-K EDGAR
  6. Aug 5, 2026S-8 EDGAR
  7. Aug 5, 202610-Q EDGAR
  8. Aug 5, 20268-K EDGAR
  9. Jul 27, 2026SCHEDULE 13G EDGAR
  10. Jun 15, 20268-K EDGAR
  11. Jun 9, 20264 EDGAR
  12. Jun 9, 20264 EDGAR
  13. Jun 9, 20264 EDGAR
  14. Jun 9, 20264 EDGAR
  15. Jun 9, 20264 EDGAR
  16. Jun 9, 20264 EDGAR
  17. Jun 9, 20264 EDGAR
  18. Jun 2, 20264 OWNERSHIP DOCUMENT EDGAR
  19. Jun 2, 20264 OWNERSHIP DOCUMENT EDGAR
  20. Jun 1, 20268-K EDGAR

The 334 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

3 open-market trades by officers, directors and large owners since October 2021: 0 buys and 3 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
May 23, 2025Wahlstrom MatsDirectorSale99,988$0.74$74.0KForm 4
Nov 22, 2023Lanfear Dennis MPresident & CEOSale223,100$2.02$450.7KForm 4
Oct 15, 2021Stilwell McDavidChief Financial OfficerSale3,507$16.80$58.9KForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Timothy G. Youngquist 2020 Irrevocable Trust13,050,623$18.3M3.7%+759,823
BlackRock, Inc.12,003,316$16.8M0.0%+1,638,242
Vanguard Capital Management LLC5,949,490$8.3M0.0%+496,728
Geode Capital Management, LLC3,685,567$5.2M0.0%+563,989
Samsara Biocapital, LLC3,428,571$4.8M0.4%No change
Kohlberg Kravis Roberts & Co. L.P.3,036,076$4.2M0.1%No change
State Street Corp2,382,305$3.3M0.0%+56,446
Two Sigma Investments, LP2,259,412$3.2M0.0%−42,589
CM Management, LLC2,100,000$2.9M1.9%No change
Alyeska Investment Group, L.P.1,733,234$2.4M0.0%−516,766
Hudson Bay Capital Management LP1,693,000$2.4M0.0%−11,980
Aqr Capital Management LLC1,330,201$1.9M0.0%+124,155
Charles Schwab Investment Management Inc1,228,069$1.7M0.0%+72,168
Panagora Asset Management Inc1,137,325$1.6M0.0%−321,985
Northern Trust Corp1,129,470$1.6M0.0%+215,670
Vanguard Fiduciary Trust Co1,015,991$1.4M0.0%+66,072
Nomura Asset Management International Inc.899,999$1.3M0.0%No change
Vanguard Portfolio Management LLC883,454$1.2M0.0%+278,929
UBS Group AG760,358$1.1M0.0%+213,149
Goldman Sachs Group Inc602,075$842.9K0.0%−94,083
Renaissance Technologies LLC563,056$788.3K0.0%+231,356
Strs Ohio395,600$553.8K0.0%+71,600
Bridgeway Capital Management, LLC391,000$547.4K0.0%−50,000
Invesco Ltd.353,922$495.5K0.0%+18,613
Bank of New York Mellon Corp319,687$447.6K0.0%+34,654

13F reports cover disclosed long positions in U.S. stocks only.

Members of Congress who traded it

1 trades disclosed by members of Congress. “Vs S&P since” is the stock’s change since the trade minus the S&P 500’s.

DateMemberTradeAmountVs S&P sinceFiling
Jan 23, 2023Shri ThanedarDemocratic, HouseSale$15,001 - $50,000+181.9%Report

Members report amounts as ranges, not exact figures. Returns are price-only (no dividends).

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53